Direxion Daily S&P Biotech Bear 3X ETF
LABD
11 hedge funds and large institutions have $20.5M invested in Direxion Daily S&P Biotech Bear 3X ETF in 2018 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 0 reducing their positions, and 4 closing their positions.
1,200% more call options, than puts
Call options by funds: $30.8M | Put options by funds: $2.37M
122% more capital invested
Capital invested by funds: $9.23M → $20.5M (+$11.3M)
0.01% more ownership
Funds ownership: 0.01% → 0.01% (+0.01%)
8% less funds holding
Funds holding: 12 → 11 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$6.09M |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.75M |
| 3 |
VF
Virtu Financial
New York
|
+$1.15M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$994K |
| 5 |
Citigroup
New York
|
+$931K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
-$277K |
| 2 |
HF
HRT Financial
New York
|
-$181K |
| 3 |
CT
CMT Trading
Chicago,
Illinois
|
-$72K |
| 4 |
Goldman Sachs
New York
|
-$71K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $7.96M | +$6.09M | +876 | +407% |
|
2
SG Americas Securities
New York
| $3.65M | +$570K | +82 | +20% |
|
|
VF
3
Virtu Financial
New York
| $2.14M | +$1.15M | +166 | +131% |
|
|
4
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $2.05M | +$994K | +143 | +104% |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $1.98M | +$1.75M | +252 | +1,326% |
|
|
6
Citigroup
New York
| $1M | +$931K | +134 | +3,350% |
|
7
Jane Street
New York
| $687K | +$653K | +94 | New |
|
8
Citadel Advisors
Miami,
Florida
| $517K | +$396K | +57 | +407% |
|
|
CS
9
Credit Suisse
Zurich,
Switzerland
| $492K | +$466K | +67 | New |
|
10
UBS Group
Zurich,
Switzerland
| $15K | +$13.9K | +2 | New |
|
|
CG
11
Cutler Group
San Francisco,
California
| $12K | +$6.95K | +1 | +100% |
|
|
12
Barclays
London,
United Kingdom
| – | -$277K | -30 | Closed |
|
|
HF
13
HRT Financial
New York
| – | -$181K | -20 | Closed |
|
|
CT
14
CMT Trading
Chicago,
Illinois
| – | -$72K | -8 | Closed |
|
|
15
Goldman Sachs
New York
| – | -$71K | -8 | Closed |
|
LABD Hedge Fund Activity: Q1 2018 in Review
11 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Direxion Daily S&P Biotech Bear 3X ETF (LABD) for Q1 2018, worth a combined $20.5M — up 122% from $9.23M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of LABD and 3 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 8 added.
The largest buyer was Morgan Stanley, adding an estimated $6.09M. The largest seller was Barclays, exiting entirely with an estimated $277K sold.
- 11 institutional investors held Direxion Daily S&P Biotech Bear 3X ETF (LABD) as of Q1 2018, down from 12 in Q4 2017.
- Funds reported $20.5M of Direxion Daily S&P Biotech Bear 3X ETF stock for Q1 2018, up 122% quarter-over-quarter.
- 3 funds opened new Direxion Daily S&P Biotech Bear 3X ETF positions in Q1 2018 and 4 closed out, a net change of -1 holder.
- The largest Direxion Daily S&P Biotech Bear 3X ETF buyer in Q1 2018 was Morgan Stanley, an estimated $6.09M added.
- The largest Direxion Daily S&P Biotech Bear 3X ETF seller in Q1 2018 was Barclays, an estimated $277K sold.
Based on aggregated 13F filings for Q1 2018.